Switzerland-based wearable health technology developer Biovotion has reached the final close of an oversubscribed CHF13m ($13.5m) series A round featuring reinsurer Swiss Re and semiconductor manufacturer STMicroelectronics.
Harmony Medical, an investment company backed by asset management group Citic also took part, as did an unnamed corporate venture capital vehicle for a global consumer-focused company, and an undisclosed institutional investor focused on the internet-of-things sector.
Founded in 2011, Biovotion has created a wearable device that can monitor vital signs such as heart rate, skin temperature, blood oxygenation and the number of steps a user takes.
The device, branded as Everion, can connect to an online platform to provide users with detailed analytics on their physiology. Biovotion intends to expand its technology into areas such as sleep, energy expenditure, respiratory rate and blood glucose.
Swiss Re and STMicroelectronics had both contributed to the $10.4m first close of the round in June 2016.